Showing 2051-2060 of 5957 results for "".
- Study Lays Foundation for Establishing Base Editing as a One-Time, Durable Treatment for Inherited Retinal Degenerationhttps://modernod.com/news/study-lays-foundation-for-establishing-base-editing-as-a-one-time-durable-treatment-for-inherited-retinal-degeneration/2480766/A new University of California, Irvine-led study indicates base editing may provide long-lasting retinal protection and prevent vision deterioration in patients with inherited retinal degeneration, specifically in Leber congenital amaurosis (LCA) patients. “Our findings demo
- Harvard Eye Associates Surgeons Implant the First AccuraSee IOPCL to Treat Macular Degenerationhttps://modernod.com/news/harvard-eye-associates-surgeons-implant-the-first-accurasee-iopcl-to-treat-macular-degeneration/2480721/Harvard Eye Associates reported that its surgeons have implanted the first AccuraSee Intraocular Pseudophakic Contact Lens (IOPCL) to improve near vision in patients with macular degeneration. The AccuraSee lens implant is placed to help magnify images and allow patients to use parts of
- Evmann Creates Roadmap to Facilitate its Development into a €1 Billion Global Companyhttps://modernod.com/news/evmann-creates-roadmap-to-facilitate-its-development-into-a-eur1-billion-global-company/2480714/Dutch Evmann Investments Holding, the parent company of VSY Biotechnology, organized its 2022 Global Leadership Meeting last week in line with its strategic plans to become a "unicorn" company. "Unicorn" is a term used in the venture capital industry to describe 
- Apellis' Pegcetacoplan Showed Continuous Effects at Month 18 in Phase 3 DERBY and OAKS Studies for Geographic Atrophy (GA)https://modernod.com/news/apellis-announces-pegcetacoplan-showed-continuous-and-clinically-meaningful-effects-at-month-18-in-phase-3-derby-and-oaks-studies-for-geographic-atrophy-ga/2480701/Apellis Pharmaceuticals announced longer-term data from the phase 3 DERBY and OAKS studies, which showed that intravitreal pegcetacoplan, an investigational, targeted C3 therapy, continued to reduce geographic atrophy (GA) lesion growth and demonstrate a favorable safety profile at month 18 for t
- EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-isabelle-lefebvre-as-chief-regulatory-officer/2480678/EyePoint Pharmaceuticals announced the appointment of Isabelle Lefebvre as Chief Regulatory Officer. Ms. Lefebvre brings more than 30 years of global regulatory affairs experience across all phases of drug development, including ophthalmic and ocular conditions. Ms. Lefebvre is su
- Using Cryo-Electron Tomography, UCI Researchers Reveal Molecular Mechanisms Underlying Mutations Within the Eye that Lead to Blindnesshttps://modernod.com/news/uc-irvine-researchers-reveal-molecular-mechanisms-of-eye-disease-using-cryo-electron-tomography/2480586/For the first time, University of California, Irvine researchers in collaboration with the Max-Planck Institute of Biochemistry, have revealed, at a molecular level, key structural determinants of the highly specialized rod outer segment (ROS) membrane architecture of the eye, which is instrument
- Using Cryo-Electron Tomography, UCI Researchers Reveal Molecular Mechanisms Underlying Mutations Within the Eye that Lead to Blindnesshttps://modernod.com/news/using-cryo-electron-tomography-uci-researchers-reveal-molecular-mechanisms-underlying-mutations-within-the-eye-that-lead-to-blindness/2480552/For the first time, University of California, Irvine researchers in collaboration with the Max-Planck Institute of Biochemistry, have revealed at a molecular level key structural determinants of the highly specialized rod outer segment (ROS) membrane architecture of the eye, which is instrum
- Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucomahttps://modernod.com/news/nicox-announces-first-patient-in-china-screened-in-the-ongoing-ncx-470-denali-phase-3-trial-in-glaucoma/2480521/Nicox SA announced that the first patient has been screened in China in the ongoing Denali phase 3 clinical trial, opening the way for new drug application (NDA) submissions in both the United States and China for NCX 470, Nicox’s lead clinical product candidate in glaucoma. Denali, wh
- Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHONhttps://modernod.com/news/mitotech-granted-orphan-drug-designation-by-fda-for-visomitin-in-lhon/2480520/Luxembourg-based Mitotech SA announced that the FDA has granted orphan drug designation (ODD) for the company’s topical cardiolipin peroxidation inhibitor, Visomitin, for the treatment of Leber’s Hereditary Optic Neuropathy (LHON), a rare inherited condition that can lead to blin
- Kubota Vision Announces Publication in Scientific Reports of Study Data for Wearable Myopia-Control Devicehttps://modernod.com/news/kubota-vision-announces-publication-in-scientific-reports-of-study-data-for-wearable-myopia-control-device/2480478/Kubota Vision announced the publication of a new paper in the journal Scientific Reports: Effect of short-term peripheral myopic defocus on ocular biometrics using Fresnel “press-on” lenses in humans. The paper